Thermo Fisher to double viral vector manufacturing capacity

By The Science Advisory Board staff writers

May 11, 2020 -- Thermo Fisher Scientific is expanding its viral vector development and manufacturing services with construction of a new commercial manufacturing site in Plainville, MA. The $180 million facility will more than double the company's current commercial viral vector capacity and support its growing gene therapy and vaccine business.

Construction of the 290,000 sq ft site is expected to be completed in 2022. The site will offer flexible and scalable laboratory and production suites with adjacent warehousing and office space. An on-site engineering laboratory will enable customers to rapidly transition to commercial-scale operations when they are ready.

The project will add over 200 jobs in the state and will complement the company's other assets in Lexington and Cambridge, MA, and Alachua, FL. The expansion project is part of Thermo Fisher's "start here, stay here" strategy to bring development and commercialization efforts to the U.S.

"Between Plainville and our other expanded sites in the U.S., we're increasing viral vector production to accelerate cell and gene therapy innovation, giving hope to more patients everywhere," said Michel Lagarde, executive vice president of Thermo Fisher Scientific.

Thermo Fisher launches SARS-CoV-2 GlobalAccess Sequencing Program
Thermo Fisher Scientific is providing 50 units of its Ion Torrent Genexus system at a subsidized price to support global COVID-19 research as part of...
Thermo Fisher Scientific optimizes NGS platform for COVID-19
To expedite genomic analysis of COVID-19 resurgent strains, Thermo Fisher Scientific has optimized its Ion AmpliSeq SARS-CoV-2 research panel for use...
Thermo Fisher, Hamilton debut DNA test system
Thermo Fisher Scientific and Hamilton have launched an automated DNA sample preparation system that extracts nucleic acids from forensic samples.
Thermo Fisher set to acquire Qiagen after all in $11.5B deal
After an on-and-off courtship, Thermo Fisher Scientific announced it is set to acquire Qiagen in a deal worth $11.5 billion. The transaction will...
Thermo Fisher, NanoPin partner on infectious disease tech
Thermo Fisher Scientific will partner with infectious diseases diagnostic company NanoPin Technologies to develop workflows for liquid chromatography-mass...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter